Literature DB >> 36201141

In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii.

Wentao Ni1, Yifan Wang2, Xinqian Ma2, Yukun He2, Jin Zhao3, Jie Guan4, Yanjun Li5, Zhancheng Gao6.   

Abstract

We investigated activities of cefiderocol combination therapy against carbapenem-resistant Acinetobacter baumannii (CR-AB). A total of 123 clinical isolates of CR-AB, including 44 cefiderocol-resistant isolates were tested. Cefiderocol functioned synergistically with tigecycline in most cefiderocol-susceptible isolates (84.8%, 67/79), but not with colistin or meropenem by checkerboard method. Cefiderocol functioned synergistically with tigecycline, colistin, and meropenem in 90.9% (40/44), 47.7% (21/44), and 79.5% (35/44) cefiderocol-resistant isolates, respectively. The time-kill assay and the in vivo Galleria mellonella model confirmed these observations. In summary, cefiderocol combined with tigecycline showed synergistic effects against both cefiderocol-susceptible and -resistant CR-AB, suggesting a potentially valuable combination regimen.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Carbapenem-resistant Acinetobacter baumannii; Cefiderocol; Colistin; Combination therapy; Meropenem; Tigecycline

Year:  2022        PMID： 36201141     DOI： 10.1007/s10096-022-04503-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   5.103


  17 in total

Review 1.  Combination therapy for treatment of infections with gram-negative bacteria.

Authors:  Pranita D Tamma; Sara E Cosgrove; Lisa L Maragakis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).

Authors:  Mical Paul; Elena Carrara; Pilar Retamar; Thomas Tängdén; Roni Bitterman; Robert A Bonomo; Jan de Waele; George L Daikos; Murat Akova; Stephan Harbarth; Celine Pulcini; José Garnacho-Montero; Katja Seme; Mario Tumbarello; Paul Christoffer Lindemann; Sumanth Gandra; Yunsong Yu; Matteo Bassetti; Johan W Mouton; Evelina Tacconelli; Jesús Rodríguez-Baño
Journal:  Clin Microbiol Infect       Date:  2021-12-16       Impact factor: 8.067

Review 3.  Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.

Authors:  Sharon Ong'uti; Mary Czech; Elizabeth Robilotti; Marisa Holubar
Journal:  Clin Infect Dis       Date:  2022-04-09       Impact factor: 9.079

Review 4.  Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.

Authors:  Pranita D Tamma; Samuel L Aitken; Robert A Bonomo; Amy J Mathers; David van Duin; Cornelius J Clancy
Journal:  Clin Infect Dis       Date:  2022-07-06       Impact factor: 20.999

Review 5.  Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.

Authors:  Chuanhai Wang; Deqing Yang; Yifan Wang; Wentao Ni
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

6.  Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.

Authors:  Toshiaki Aoki; Hidenori Yoshizawa; Kenji Yamawaki; Katsuki Yokoo; Jun Sato; Shinya Hisakawa; Yasushi Hasegawa; Hiroki Kusano; Masayuki Sano; Hideki Sugimoto; Yasuhiro Nishitani; Takafumi Sato; Masakatsu Tsuji; Rio Nakamura; Toru Nishikawa; Yoshinori Yamano
Journal:  Eur J Med Chem       Date:  2018-06-08       Impact factor: 6.514

7.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.

Authors:  Evelina Tacconelli; Elena Carrara; Alessia Savoldi; Stephan Harbarth; Marc Mendelson; Dominique L Monnet; Céline Pulcini; Gunnar Kahlmeter; Jan Kluytmans; Yehuda Carmeli; Marc Ouellette; Kevin Outterson; Jean Patel; Marco Cavaleri; Edward M Cox; Chris R Houchens; M Lindsay Grayson; Paul Hansen; Nalini Singh; Ursula Theuretzbacher; Nicola Magrini
Journal:  Lancet Infect Dis       Date:  2017-12-21       Impact factor: 71.421

8.  Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.

Authors:  Yifan Wang; Yanjun Li; Jin Zhao; Jie Guan; Wentao Ni; Zhancheng Gao
Journal:  Ann Transl Med       Date:  2022-03

9.  Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.

Authors:  Matteo Bassetti; Roger Echols; Yuko Matsunaga; Mari Ariyasu; Yohei Doi; Ricard Ferrer; Thomas P Lodise; Thierry Naas; Yoshihito Niki; David L Paterson; Simon Portsmouth; Julian Torre-Cisneros; Kiichiro Toyoizumi; Richard G Wunderink; Tsutae D Nagata
Journal:  Lancet Infect Dis       Date:  2020-10-12       Impact factor: 71.421

Review 10.  Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: How viable are the current options?

Authors:  J Nicholas O'Donnell; Vibert Putra; Thomas P Lodise
Journal:  Pharmacotherapy       Date:  2021-07-22       Impact factor: 4.705
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.